UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Effector Therapeutics, a US-based cancer treatment developer spun out of University of California, (UC) San Francisco, agreed to a reverse merger with special purpose acquisition company Locust Walk Acquisition Corporation today. Locust Walk is listed on Nasdaq Capital Market under the ticker symbol LWAC. It raised $175m in its initial public offering in January 2021…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.